Arax Capital Partners has funded metabolic biomarker company Biocrates Life Science AG with €1.2m as a first tranche of a fundraising round.
This is the second deal inked by the GP via Wisequity V, which closed on its €260m hard-cap in July 2019
Pascal Meysson joins from Alcentra and has previous experience at Deutsche Bank and Charterhouse
Mirabaud is reportedly planning to invest via its Living Heritage private equity fund
HIG invested from its Growth Buyout Equity Fund III to acquire Vernacare from Palatine